Skip to Content

Griseofulvin Pregnancy and Breastfeeding Warnings

Griseofulvin is also known as: Fulvicin P/G, Fulvicin U/F, Grifulvin V, Gris-PEG, Grisactin 250, Grisactin 500, Grisactin Ultra, Griseofulicin, Griseofulvic

Medically reviewed by Last updated on Dec 3, 2018.

Griseofulvin Pregnancy Warnings

Griseofulvin is assigned to pregnancy category C. Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancies; however, there are reports of congenital anomalies, including cases of conjoined twins in two women, as well as increased risk of spontaneous abortion. The manufacturer considers griseofulvin use to be contraindicated during pregnancy.

See references

Griseofulvin Breastfeeding Warnings

There are no data on the excretion of griseofulvin into human milk.

See references

References for pregnancy information

  1. Rosa FW, Hernandez C, Carlo WA "Griseofulvin teratology, including two thoracopagus conjoined twins." Lancet 1 (1987): 171
  2. Knudsen LB "No association between griseofulvin and conjoined twinning." Lancet 2 (1987): 1097
  3. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.

References for breastfeeding information

  1. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.